TP-04: An investigational therapeutic being studied for the potential treatment of papulopustular rosacea

What is TP-04?

TP-04 is a topical, aqueous gel formulation of lotilaner in development for the potential treatment of papulopustular rosacea (PPR).1

According to the National Rosacea Society, approximately 16 million people in the US are affected by rosacea,2 a chronic skin disease characterized by facial redness, inflammatory lesions, burning, and stinging. PPR, estimated to occur in 18% to 28% of patients with rosacea, can result in redness, swelling, and/or pus-filled bumps.3-7

TP-04 is1:

Read about a chronic condition characterized by facial redness, flushing, and visible blood vessels.

LEARN MORE ABOUT ROSACEA
Reference:

1. [Tarsus Initiates Phase 2 Trial Evaluating TP-04, a Novel, Aqueous Gel Formulation of Lotilaner, for the Treatment of Papulopustular Rosacea.] Press release. March 13, 2023. 2. Rosacea now estimated to affect at least 16 million Americans. January 25, 2023. Rosacea.org. https://www.rosacea.org/rosacea-review/2010/winter/rosacea-now-estimated-to-affect-at-least-16-million-americans 3. Abram et al. Prevalence of rosacea in an Estonian working population using standard classification. Acta Derm Venereol 2010; 90: 269-73. 4. Berg M, Liden S. An epidemiological study of rosacea. Acata Derm Venereol 1989; 69: 419-423. 5. Gether et al. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Brit J Dermatol 2018; 179: 282-289. 6. Kyriakis et al. Epidemiologic aspects of rosacea. J Am Acad Dermatol 2005; 53: 918-919. 7. Tan et al. Prevalence of rosacea in the general population of Germany and Russia – the RISE study. J Eur Acad Dermatol Venereol 2016; 30: 428-434.

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

Opt-in
This field is for validation purposes and should be left unchanged.